A CORRELATIVE STUDY SHOWING THE RELATIONSHIP OF SALIVARY URIC ACID LEVEL WITH THE METABOLIC SYNDROME COMPONENTS & ITS SEVERITY

Similar documents
METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS

International Journal of Pharma and Bio Sciences

Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya

Metabolic Syndrome: Why Should We Look For It?

Metabolic Syndrome: What s in a name?

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

Obesity in the pathogenesis of chronic disease

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Association of hypothyroidism with metabolic syndrome - A case- control study

Established Risk Factors for Coronary Heart Disease (CHD)

By: Dr Mehrnoosh Shanaki

Serum ferritin and high sensitivity C-reactive protein are associated with metabolic syndrome in Japanese men and women

THE PHARMA INNOVATION - JOURNAL The Metabolic Syndrome in Menopausal Women: No Links with Endogenous Intoxication

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

CHAPTER 3 DIABETES MELLITUS, OBESITY, HYPERTENSION AND DYSLIPIDEMIA IN ADULT CENTRAL KERALA POPULATION

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Metabolic Syndrome.

Frequency of Dyslipidemia and IHD in IGT Patients

Increased oxidative stress according to number of risk factors in metabolic syndrome patients

300 Biomed Environ Sci, 2018; 31(4):

Development of the Automated Diagnosis CT Screening System for Visceral Obesity

International Journal of Pharma and Bio Sciences PLATELET VOLUME INDICES (PVI) IN METABOLIC SYNDROME (MS) ABSTRACT

Page 1. Disclosures. Background. No disclosures

Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:

Relations of body weight status in early adulthood and weight changes until middle age with metabolic syndrome in the Chinese population

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

Ko G T C, Tang J S F. Conclusion: MES is not uncommon among Hong Kong Chinese. Further studies on the management and prevention of MES are indicated.

Diabetes Mellitus: A Cardiovascular Disease

Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Socioeconomic status risk factors for cardiovascular diseases by sex in Korean adults

Total risk management of Cardiovascular diseases Nobuhiro Yamada

290 Biomed Environ Sci, 2016; 29(4):

MOLINA HEALTHCARE OF CALIFORNIA

Frequency of Metabolic Syndrome on Diabetes Mellitus Patients in Surabaya

Metabolic Syndrome in Hypertensive Nigerians: Risk Factor Analysis

Waist Circumference and Waist-to-Height Ratio as Predictors of Cardiovascular Disease Risk in Korean Adults

A study of waist hip ratio in identifying cardiovascular risk factors at Government Dharmapuri College Hospital

Association of Uric acid with type II diabetes

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

JMSCR Volume 03 Issue 04 Page April 2015

Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes

Metabolic syndrome and insulin resistance in an urban and rural adult population in Sri Lanka

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus

Metabolic Syndrome and Chronic Kidney Disease

Diabetes Care 31: , 2008

Abdominal volume index and conicity index in predicting metabolic abnormalities in young women of different socioeconomic class

Relationship between cardiovascular risk factors and traditional Chinese constitution in subjects with high-normal blood pressure

A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

Lipoprotein Particle Profile

Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH

The Metabolic Syndrome Prof. Jean-Pierre Després

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Correlation between fasting insulin and blood pressure in obese and non-obese middle aged Indian diabetic adults

Clinical Value of Serum Uric Acid in Patients with Suspected Coronary Artery Disease

Alona Angosta, PhD, APRN, NP-C University of Nevada, Las Vegas School of Nursing

Trends In CVD, Related Risk Factors, Prevention and Control In China

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Serum Retinol-binding Protein 4 Levels in Patients with Diabetic Retinopathy

Clinical surrogate markers for predicting metabolic syndrome in middle-aged and elderly Chinese

Hypertriglyceridemia and the Related Factors in Middle-aged Adults in Taiwan

Risk Factors for Heart Disease

Cardiovascular Complications of Diabetes

5/28/2010. Pre Test Question

Atherogenic Index as a Predictor of Cardiovascular Risk among Women with Different Grades of Obesity

Relationship between Biological Markers, Metabolic Components, Lifestyles, and Impaired Fasting Glucose in Male Workers

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Age and Sex Differences the Clustering of Metabolic Syndrome Factors: Association with Mortality Risk

... CME/CPE QUIZ... CME/CPE QUESTIONS

Salivary uric acid as a noninvasive biomarker of metabolic syndrome

MULTIFACTORIAL ANALYSIS OF CARDIOVASCULAR RISK FACTORS IN A GROUP OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

EFFECT OF LYCOPENE IN TOMATO SOUP AND TOMATO JUICE ON THE LIPID PROFILE OF HYPERLIPIDEMIC SUBJECTS

Causes of Different Estimates of the Prevalence of Metabolic Syndrome in Korea

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Text-based Document. Predicting Factors of Body Fat of Metabolic Syndrome Persons. Downloaded 13-May :51:47.

CFH Trust Heart Fitness Screening Test Guidance

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions

Predictive value of overweight in early detection of metabolic syndrome in schoolchildren

Shihui Fu 1,2, Ying Lin 2, Leiming Luo 1* and Ping Ye 1*

Know Your Number Aggregate Report Single Analysis Compared to National Averages

METABOLIC SYNDROME IN A JORDANIAN COHORT: DEMOGRAPHY, COMPLICATIONS AND PREDICTORS OF CARDIOVASCULAR DISEASES

Relationship of Body Mass Index, Waist Circumference and Cardiovascular Risk Factors in Chinese Adult 1

ORIGINAL ARTICLE. Abstract. Introduction

Rehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI. James S. Krause, PhD

Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study

902 Biomed Environ Sci, 2014; 27(11):

Study of fixed dose combination for the management of cardiovascular diseases

ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,

Fructose, Uric Acid and Hypertension in Children and Adolescents

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Transcription:

Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Copyrights@2016 Received: 4 th Mar 2016 Revised: 22 nd Mar 2016 Accepted: 24 th Mar 2016 Research article A CORRELATIVE STUDY SHOWING THE RELATIONSHIP OF SALIVARY URIC ACID LEVEL WITH THE METABOLIC SYNDROME COMPONENTS & ITS SEVERITY Mrs. Bhagyashree. N 1, Dr. C. Ramaswamy 2, Dr. Ganesh. M 3 1 Assistant Professor, Dept of Physiology, A C S Medical College & Hospital and Ph D Scholar, Saveetha University, Chennai, 2 Professor & Research Guide, Saveetha University, Chennai, 3 Professor, A C S Medical College & Hospital, Chennai. ABSTRACT Introduction: Uric acid, the metabolic product of Purine nucleotide, increased in the metabolic syndrome condition which is a major risk factor for cardiovascular disease and diabetes. The metabolic syndrome comprises components of some complex interrelated factors such as dysglycemia, raised blood pressure, elevated triglyceride levels, low high density lipoprotein cholesterol levels, and obesity. As uric acid level in serum & saliva increases in metabolic syndrome, testing of salivary uric acid may be a useful noninvasive approach for monitoring cardio metabolic risk. Objective: To find out the correlation, if any, between salivary uric acid and the components of metabolic syndrome and its severity. Materials and methods: Among the patients came to hospital for metabolic syndrome clinic, the volunteers without any known condition that affect salivation were recruited as subjects (195) for the study. The subjects were divided into three groups based on the number of components of the metabolic syndrome as group I (having 3components), group II (having more than 3 components) and group III (having 1 or 2 components) and their height, weight, blood pressure, waist circumference, was measured and blood test with lipid profile and fasting blood glucose were obtained. Saliva samples were collected and salivary uric acid levels were determined in all the subjects. Result & Discussion: Salivary uric acid was significantly elevated in subjects with more number of metabolic abnormalities (Group II), p = < 0.0001. Significant correlations were seen when comparing the Salivary uric acid level with either of the WC (r = 0.343, p = <0.0001), systolic BP (r = 0.272, p = < 0.0001), diastolic BP (r = 0.362, p = <0.0001), FBG (r = 0.224, p = 0.0016), Total Cholesterol (r = 0.145, p = 0.042), Triglycerides (r = 0.276, p = <0.0001), HDL C (r = -0.407, p = <0.0001), LDL C (r = 0.173, p = 0.0156) levels. Conclusion: Salivary uric acid can be used as a non invasive biomarker for monitoring the metabolic syndrome. Key words: Salivary uric acid, biomarker, metabolic syndrome. *Corresponding author: Mrs. Bhagyashree. N, Dept of Physiology, A C S Medical College & Hospital, India E-mail: bhagyashivanugraha@gmail.com Copyright: 2016 Mrs. Bhagyashree. N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited INTRODUCTION Uric acid is a final enzymatic product from purine degradation, contributes to the antioxidant capacity of both blood and saliva. However, the enzyme responsible for its production also generates free radicals, hence several studies indicted uric acid as pro inflammatory and pro oxidant agent (Maria Soukup et al 2012). There is a growing body of evidence to show that hyperuricemia or elevated serum uric acid levels, even within the normal range, are associated with metabolic syndrome and its components (Yongfeng Tian et al 2015, Chen Li Ying et al 2007). International Journal of Applied Biology and Pharmaceutical Technology Page: 168

The metabolic syndrome include the complex interrelated factors such as dysglycemia, raised blood pressure, elevated triglyceride levels, low high density lipoprotein cholesterol levels, and obesity (K.G.M.M. Alberti et al 2009). The factors of metabolic syndrome (MS) form the major risk factors for cardiovascular disease (CVD) and diabetes. It has been widely demonstrated that metabolic syndrome is associated with 2 to 3 fold increase in CVD risk and nearly 7 fold for incidence of type 2 diabetes mellitus (DM). Metabolic syndrome and hyperuricemia are important risk factors for cardiovascular disease (Wen-Ko Chion et al 2010, A.N. Al Isa et al 2013) and the cardiovascular disease is the leading cause of death and disability worldwide (Falcone C et al 2014). As uric acid level in serum & saliva increases in metabolic syndrome, the testing of salivary uric acid level may be a useful noninvasive approach for monitoring cardio metabolic risk. Regardless of whether it plays a causative role or not, it is an indicator of metabolic disturbances, and hence uric acid level in saliva may be a useful biomarker for identifying high risk patients and monitoring the response to lifestyle interventions (Maria Soukup et al 2012). OBJECTIVE To find out the correlation, if any, between the salivary uric acid level and the various components and severity of metabolic syndrome. MATERIALS AND METHODS The study was carried out on 195 volunteers who were come to hospital and were diagnosed metabolic syndrome patients and treated were recruited for the present study. The diagnostic criteria for metabolic syndrome were according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria ( 3 of 5 risk factors). The patients included in this study were divided into three groups on the basis of metabolic syndrome criteria, each comprising of 65 subjects. Group I: Subjects with any three components of metabolic syndrome (normal MS group) Group II: Subjects with more than three components of metabolic syndrome (severe MS group) Group III: Subjects with less than three components of metabolic syndrome (control group) Exclusion criteria: Subjects with conditions known to affect salivation, uric acid, or inflammatory biomarkers including gout, renal insufficiency, autoimmune disease, active infection, pregnancy were excluded (Maria Soukup et al 2012). The study was carried out in the department of Physiology, A C S Medical College and Hospital, Chennai. The participants were from A C S Medical College and Hospital, Saveetha Medical College and Hospital, Chennai. The study commenced after getting the approval from the Institutional Human Ethical Committee (IHEC), Saveetha University, Chennai. Age & sex matched subjects were recruited for the study. The data were collected from the participants after giving detailed explanation about the procedure and their cooperation and willingness was obtained with written informed consent. A detailed clinical history and information regarding oral health status of all the subjects were taken. Relevant past history, family history, any drug history, personal history like smoking, alcoholism etc were taken. The following parameters were studied using the method as mentioned. Waist circumference (WC) -- was measured at the end of normal expiration, between the lower rib margin and the iliac crest. Systolic and Diastolic Blood Pressure was recorded by Sphygmomanometer. The blood samples were collected from all the subjects after overnight fast to study -- Fasting Blood Glucose(FBS), Total Cholesterol(TC), Triglycerides(TG), High Density Lipoprotein cholesterol (HDL - C), Low Density Lipoprotein cholesterol (LDL - C). Saliva samples to study uric acid level were collected from all the subjects in fasting conditions during morning in a sterile container for the measurement of salivary uric acid. Measurement of salivary uric acid was done with semi automated biochemical analyzer by enzymatic colorimetric method. STATISTICAL ANALYSIS Statistical analyses were performed using SAS 9.2 version. All the variables of Table 1 were analyzed between the groups with ANOVA. Correlations were investigated by calculating Pearson s correlation coefficient for all the subjects. It was used to investigate correlations between salivary uric acid and the components of metabolic syndrome. Statistical significance was considered if the p value is less than 0.05. International Journal of Applied Biology and Pharmaceutical Technology Page: 169

RESULTS The results of the present study (Table 1, Figure 1) showed the following data. The mean age of the study group was 49.32 ± 8.462 which showed no significant difference among the study groups. It showed that Salivary uric acid levels were significantly elevated in subjects with more number of metabolic abnormalities (Group II), p = < 0.0001. Significant positive correlations were seen when the Salivary uric acid is compared with WC (r = 0.343, p = <0.0001), systolic BP (r = 0.272, p = < 0.0001), diastolic BP (r = 0.362, p = <0.0001), FBG (r = 0.224, p = 0.0016), Total Cholesterol (r = 0.145, p = 0.042), Triglycerides (r = 0.276, p = <0.0001), LDL C (r = 0.173, p = 0.0156) whereas the Salivary uric acid levels were negatively correlated with HDL (r = -0.407, p = <0.0001) levels. Table 1: Comparison of different components of metabolic syndrome in study groups (Values expressed as mean ± SD) Variable Total (195) Group I (65) Group II (65) Group III (65) P - value Age 49.32 ± 8.462 49.72 ± 8.06 49.92 ± 7.39 48.30 ± 9.77 0.496 NS Waist circumference 96.87 ± 9.821 97.44 ± 8.76 102.36 ± 9.06 90.8 ± 8.05 (WC) <0.0001*** Systolic BP (mmhg) 134.86 ± 10.34 136.2 ± 7.41 138.76 ± 9.78 129.6 ± 11.30 <0.0001*** Diastolic BP (mmhg) 83.99 ± 7.329 83.87 ± 6.93 88.09 ± 6.35 80.01 ± 6.41 <0.001** Fasting Blood Glucose (mg/dl) 133.67 ± 32.731 136.89 ±37.68 141.10 ±26.66 123.01±30.57 <0.0039** Total Cholesterol 158.96 ± 24.787 161.84 ±21.19 164.26 ±27.12 150.77 ±23.9 <0.0038** (mg/dl) Triglycerides(mg/dl) 151.05 ± 40.718 145.95 ±36.62 174.35 ±48.34 132.85 ±20.79 <0.0001*** HDL C (mg/dl) 46.03 ± 5.892 47.44 ±5.04 41.59 ± 5.61 49.06 ± 4.12 <0.0001*** LDL C (mg/dl) 77.48 ± 20.679 78.30 ± 16.76 79.73 ± 22.11 74.40 ± 22.59 0.3151 NS Salivary uric acid (mg/dl) 3.91 ± 1.203 3.59 ± 0.86 5.04 ± 1.00 3.06 ± 0.70 <0.0001*** NS Not significant; ** Significant; *** Highly significant. Figure 1: Mean salivary uric acid level (mg/dl) in different study groups. DISCUSSION Metabolic syndrome, a major risk factor associated with cardiovascular disease is an increasingly common medical problem not only in developed countries, but also in the developing countries. Since metabolic syndrome involves complex interrelated components, it is essential to identify a common bio-marker (preferably the one that could have determined by non invasive technique) which would enable the society to participate in screening program and can monitor the progression of the disease and prevent the further complications. International Journal of Applied Biology and Pharmaceutical Technology Page: 170

This study attempted to identify salivary uric acid as one such bio-marker for metabolic syndrome as recently, the association between metabolic syndrome and elevated serum uric acid level were reported in literature (Ju Mi Leeet al 2012, Shi Dou Lin et al 2006). In 2006, Shi Dou Lin et al reported that mean serum uric acid level increased as the number of metabolic factors increased and abnormal TG had the most influence on serum uric acid. Further, the work of Ju Mi Lee et al in 2012 showed that the number of metabolic abnormalities increased gradually with increasing serum uric acid levels. Because a linear relationship exists between serum and salivary uric acid (SUA) concentration, this study was carried out by estimating the salivary uric acid level in different metabolic syndrome groups. The result of the present study indicates that the mean salivary uric acid level is proportionately increased with the increase in the components of metabolic syndrome. In the present work, the group II (severe MS) with more than 3 components of metabolic syndrome showed highly significant increase in SUA level (p = <0.0001) than the group I (having 3 components) and group III (with 1 or 2 components). Even when compared SUA level between the groups I and II, group II and III and group I and III, it showed significant results. So, the present study clearly indicates that salivary uric acid level increases with the severity of the disease and clearly supports the previous study of Ju Mi Lee et al and also reiterates that not only serum uric acid level but also salivary uric acid level correlate with severity of the metabolic syndrome component. The present study also revealed that each and every components of metabolic syndrome significantly correlated with the salivary uric acid level. Here, except, the HDL level which showed negative correlation, all the other components (WC, BP, FBS, Cholesterol, TG) had positive correlation with salivary uric acid level. Hyperuricemia is commonly observed in metabolic syndrome (Zohreh Soltani et al 2013) and it plays a role in the development of metabolic syndrome (Ju Mi Lee et al 2012, Shi Dou Lin et al 2006). The proposed mechanisms related to these findings may include effect of uric acid on endothelial dysfunction (Shi Dou Lin et al 2006, Zohreh Soltani et al 2013) and overproduction of reactive oxygen species (ROS) (Zohreh Soltani et al 2013). As, uric acid have been shown to inhibit endothelial NO bioavailability and because insulin requires endothelial NO to stimulate skeletal muscle glucose uptake, hyperuricemia may also have a causal role in the pathogenesis of insulin resistance (Adriana Iliesin et al 2010). One other mechanism linking hyperinsulinemia with hyperuricemia may be explained by a decreased renal excretion of uric acid (A.N. Al Isa et al 2013). It was well established that hyperuricemia induces intracellular ROS production in adipose cells. Since oxidative stress in adipocytes has been considered as a major factor of insulin resistance, hyperuricemia induced oxidative stress in adipose tissue might play a key role in these dysregulations (Zohreh Soltani et al 2013). As the salivary uric acid having positive correlation with serum uric acid, one can assume that the above observations clearly support the findings of the present study also. Since measurement of salivary uric acid is non invasive, relatively cheap and less time consuming, it can be used for screening of metabolic syndrome population thereby reduces the cardiovascular risk too. Present study has got some limitations as the oral health status was self reported and detailed information regarding their emotional status were not collected which could otherwise affect either salivation or uric acid level. However, exploration of the present result in this approach are needed which will be of use for all the clinicians and they can incorporate into their day to day practice. CONCLUSION The result of the present study clearly established that the salivary uric acid levels have significant correlation with the different components of the metabolic syndrome and also it increases proportionate with the severity of metabolic syndrome. So we could conclude that salivary uric acid can be used as a non invasive biomarker for monitoring the metabolic syndrome. Larger follow up studies are needed to prove the result of present study. ACKNOWLEDGEMENTS Authors would like to deliver sincere thanks to the Department of Physiology, A C S Medical College & Hospital and Saveetha Medical College & Hospital, Chennai for providing the facilities to carry out research work. International Journal of Applied Biology and Pharmaceutical Technology Page: 171

REFERENCES A. N. A Isa, A. O. Akanji. (2013). The association of uric acid with metabolic syndrome among Kuwaiti adolescents. Health 5 953 957. Adriana Iliesiu, Alexandru Campeanu, Dinu Dusceac. (2010). Serum uric acid and cardiovascular disease. (Editorials) MAEdiCA. A Journal of Clinical Medicine, volume 5 No. 3. 186 192. Chen Li ying +, Zhu Wen hua, (2007). Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B 8(8): 593 598. Falcone C, Colonna A, Bozzini S, Matrone B, Guasti L, Paganini EM, Falcone R and Pelissero G. (2014). Cardiovascular Risk Factors and Sympatho vagal Balance: Importance of Time domain Heart Rate Variability. J Clin Exp Cardiolog, 5:2. Ju Mi Lee, Hyeon Chang Kim, Hye Min Cho, (2012). Association between serum uric acid level and metabolic syndrome. J Prev Med Public Health 45(3): 181 187. K.G.M.M. Alberti, Robert H. Eckel, Scott M. Grundy, Paul Z. Zimmet, James I. Cleeman, Karen A. Donato, Jean- Charles Fruchart, W. Philip T. James, Catherine M. Loria and Sidney C, Smith, Jr. (2009). Harmonizing the Metabolic Syndrome : A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 120:1640-1645. Maria Soukup, Izabela Beisiada (2012). Salivary Uric acid as a noninvasive biomarker of metabolic syndrome. Diabetology & Metabolic Syndrome, 4:14. Shi Dou Lin, Dong Hwa Tsai, Shang Ren Hsu. (2006). Association between Serum Uric Acid Level and Components of the Metabolic Syndrome. J Chin Med Assoc 69(11): 512 516. Wen Ko Chion, Ming Hsu Wang, (2010). The Relationship between Serum Uric Acid Level and Metabolic Syndrome: Differences by Sex and Age in Taiwanese. J Epidemiol 20(3): 219 224. Yongfeng Tian, Kang Chen, Zongyan Xie. (2015).The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the Dyslipidemia International Study; BMC Cardiovascular Disorders, July. Zohreh Soltani, Kashef Rasheed, Daniel R. Kapusta (2013). Potential role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is it Time for Reappraisal? Curr Hypertens Rep. June; 15 (3): 175 181. International Journal of Applied Biology and Pharmaceutical Technology Page: 172